Subject(s)
Anesthesia/methods , Aortic Valve Insufficiency/genetics , Cardiac Surgical Procedures/methods , Pharmacogenomic Testing/methods , Polymorphism, Genetic/genetics , Anesthesia/adverse effects , Aortic Valve Insufficiency/diagnosis , Aortic Valve Insufficiency/surgery , Cardiac Surgical Procedures/adverse effects , Genetic Testing/methods , Humans , Male , Middle AgedSubject(s)
Cardiac Catheterization/methods , Heart Valve Prosthesis Implantation/methods , Tricuspid Valve Insufficiency/diagnostic imaging , Tricuspid Valve Insufficiency/surgery , Tricuspid Valve/diagnostic imaging , Tricuspid Valve/surgery , Adult , Echocardiography, Transesophageal/methods , Humans , MaleABSTRACT
Understanding the different mechanisms of vasoconstrictors is crucial to their optimal application to clinically diverse shock states. We present a comprehensive review of conventional, rescue, and novel vasoactive agents including their pharmacology and evidence supporting their use in vasodilatory shock. The role of each drug in relation to the Surviving Sepsis Guidelines is discussed to provide a context of how each one fits into the algorithm for treating vasodilatory shock. Rescue agents can be utilized when conventional medications fail, although there are varying levels of evidence on their clinical effectiveness. In addition, novel agents for the treatment of vasodilatory shock have recently emerged such as ascorbic acid and angiotensin II. Ascorbic acid has been used with some success in vasoplegia and is currently undergoing a more rigorous evaluation of its utility. Angiotensin II (Ang-2) is the newest available vasopressor for the treatment of vasodilatory shock. In addition to its catecholamine-sparing properties, it has been shown to hold promising mortality benefits in certain subsets of critically ill patients.
